KCS Wealth Advisory’s AbbVie ABBV Stock Holding History

KCS Wealth Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$220K	Sell	1,475 -92	-6%	-$13.5K	0.09%	129
2023 Q2	$211K	Buy	1,567 +85	+6%	+$12.5K	0.07%	144
2023 Q1	$236K	Sell	1,482 -30	-2%	-$4.59K	0.09%	136
2022 Q4	$244K	Hold	1,512	–	–	0.1%	136
2022 Q3	$203K	Buy	1,512 +11	+0.7%	+$1.58K	0.09%	140
2022 Q2	$230K	Buy	1,501 +50	+3%	+$7.64K	0.1%	140
2022 Q1	$235K	Sell	1,451 -100	-6%	-$14.5K	0.11%	148
2021 Q4	$210K	Buy	+1,551	New	+$183K	0.08%	154
2019 Q4	–	Sell	-2,092	Closed	-$158K	–	150
2019 Q3	$158K	Buy	+2,092	New	+$143K	0.11%	162
2018 Q4	–	Sell	-2,151	Closed	-$203K	–	148
2018 Q3	$203K	Sell	2,151 -1,285	-37%	-$122K	0.19%	142
2018 Q2	$318K	Sell	3,436 -210	-6%	-$20.5K	0.3%	121
2018 Q1	$345K	Sell	3,646 -491	-12%	-$53.9K	0.31%	121
2017 Q4	$400K	Buy	+4,137	New	+$390K	0.39%	101

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KCS Wealth Advisory's ABBV Position: Q3 2023 in Review

KCS Wealth Advisory reduced its AbbVie (ABBV) stake by 5.9% in Q3 2023, selling an estimated $13.5K and leaving 1,475 shares worth $220K. The position accounts for 0.09% of the portfolio, ranked #129.

KCS Wealth Advisory first reported a position in ABBV in Q4 2017 and has held it in 13 quarters since. The position peaked at $400K in Q4 2017. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

KCS Wealth Advisory held 1,475 shares of AbbVie worth $220K as of Q3 2023.
KCS Wealth Advisory sold 92 AbbVie shares in Q3 2023, an estimated $13.5K.
AbbVie made up 0.09% of KCS Wealth Advisory's portfolio in Q3 2023, its #129 holding.
KCS Wealth Advisory first reported a position in AbbVie in Q4 2017 and has held it in 13 quarters since.
KCS Wealth Advisory's AbbVie position peaked at $400K in Q4 2017.
3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on KCS Wealth Advisory's 13F filing for Q3 2023, filed 3 Nov 2023.